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AbstrAct
Introduction NKR-2 are autologous T cells genetically 
modified to express a chimeric antigen receptor (CAR) 
comprising a fusion of the natural killer group 2D 
(NKG2D) receptor with the CD3ζ signalling domain, which 
associates with the adaptor molecule DNAX-activating 
protein of 10 kDa (DAP10) to provide co-stimulatory signal 
upon ligand binding. NKG2D binds eight different ligands 
expressed on the cell surface of many tumour cells and 
which are normally absent on non-neoplastic cells. In 
preclinical studies, NKR-2 demonstrated  
long-term antitumour activity towards a breadth of tumour 
indications, with maximum efficacy observed after multiple 
NKR-2 administrations. Importantly, NKR-2 targeted 
tumour cells and tumour neovasculature and the local 
tumour immunosuppressive microenvironment and this 
mechanism of action of NKR-2 was established in the 
absence of preconditioning.
Methods and analysis This open-label phase I study will 
assess the safety and clinical activity of NKR-2 treatment 
administered three times, with a 2-week interval between 
each administration in different tumour types. The study 
will contain two consecutive segments: a dose escalation 
phase followed by an expansion phase. The dose 
escalation study involves two arms, one in solid tumours 
(five specific indications) and one in haematological 
tumours (two specific indications) and will include three 
dose levels in each arm: 3×108, 1×109 and 3×109 NKR-2 
per injection. On the identification of the recommended 
dose in the first segment, based on  
dose-limiting toxicity occurrences, the study will expand 
to seven different cohorts examining the seven different 
tumour types separately. Clinical responses will be 
determined according to standard Response Evaluation 
Criteria In Solid Tumors (RECIST) criteria for solid tumours 
or international working group response criteria in 
haematological tumours.
Ethics approval and dissemination Ethical approval has 
been obtained at all sites. Written informed consent will 
be taken from all participants. The results of this study 
will be disseminated through presentation at international 
scientific conferences and reported in peer-reviewed 
scientific journals.
trial registration number NCT03018405, EudraCT  
2016-003312-12; Pre-result.
IntroductIon
cAr t cell therapy
The chimeric antigen receptor (CAR) is an arti-
ficial construct that endows T cells with prede-
termined specificity.1 Prior to adoptive transfer, 
they have to be expanded in vitro to reach ther-
apeutically sufficient numbers. In this manner, 
large numbers of tumour antigen-specific 
T cells can be rapidly generated for use in 
adoptive cell therapy. The CAR itself has 
developed through several generations but 
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Protocol
strengths and limitations of this study
 ► Standard dose escalation phase and an expansion 
phase to investigate for the first time the safety and 
initial clinical activity of NKR-2 (natural killer group 
2D (NKG2D)-based chimeric antigen receptor (CAR) 
T cells retrovirally modified) in a multiple injection 
schedule.
 ► Phase I study exploiting the multiple ligand targeting 
capability of human NKG2D by assessing the 
safety and initial clinical activity of NKR-2 against 
a broad range of tumour indications, including 
haematological and solid tumour types.
 ► Based on the unique NKR-2 mode of action, 
NKR-2 will be administered without any prior 
preconditioning.
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has largely followed the configurations of extracellular 
antigen-binding domain (most commonly a single-chain 
variable fragment (scFv) derived from an antibody), a trans-
membrane domain and intracellular signalling domains. At 
present, second-generation formats tend to predominate 
featuring a co-stimulatory signalling domain (eg, CD28, 
4-1BB) fused to a T cell-activating domain (eg, CD3ζ).1 2
The CD19-specific CAR provides the paradigm against 
which other CAR approaches are currently measured 
due to the impressive clinical responses seen in early 
phase clinical trials targeting B cell malignancies. Reports 
of initial objective clinical responses in 70–90% of 
patients with advanced chemoresistant B cell leukaemia 
have fuelled interest in the area with the number of 
CD19-targeted CAR T cell trials rapidly rising within the 
last few years.3 4 The CD19-CAR T cell therapy approach 
is based on a ‘transplant procedure-like’ approach, that is, a 
single CAR T cell infusion in preconditioned (lympho-
depleted) patients and for which persistence, expansion 
and survival of the transferred T cells are crucial.3 4 All 
preconditioning regimens follow a similar concept where 
there is a transient depletion of circulating lymphoid cell 
populations to provide ‘space’ for the adoptively trans-
ferred T cells to occupy.5 6 Additional beneficial effects of 
preconditioning include the production of homeostatic 
cytokines and dampening of suppressive factors such as 
regulatory T cells, thereby providing a window of immu-
nological opportunity to target the tumour.
However, single-target therapy may select for and spur 
escape variants by clonal selection or antigen loss. Several 
CD19-specific therapies indeed evidenced cases of relapse 
resulting from CD19 antigen loss in leukaemia cells post-
CD19-specific CAR T cell therapy.7–10 Furthermore, these 
therapies are also associated with significant levels of 
toxicity,11 12 including cytokine release syndrome (CRS), 
neurotoxicity and on-target off-tumour toxicity against 
normal cells (eg, CD19-specific CAR T cells also target 
normal B cells expressing CD19, causing prolonged B cell 
aplasia and hypogammaglobulinaemia13 14). Moreover, 
anaphylaxis reaction to the foreign components of the 
CAR (eg, most CARs use scFv from murine origin, which 
might potentially induce transgene-specific humoural 
and cellular immune responses against the murine 
domain15–17) will impact drastically the safety of multiple 
injection schedule.18 The risk/benefit is clearly biased 
towards benefit since these patients have highly advanced 
cancer with little, if any, alternative effective therapeutic 
option. However, this toxicity does provide a level of 
patient selection that impacts recruitment onto current 
trials and the wider applicability for the general patient 
population.
By contrast, outside of the B cell malignancy setting, the 
CAR T cell approach has met with much reduced levels 
of clinical success.2 Notably, apart from CD19, there are 
only a few examples of normal cell lineages that can be 
safely eliminated along with malignant cells that share the 
targeted antigen, even within haematological malignancies. 
Targeting an antigen on tumour cells that is also present on 
normal cells, for example, on the myeloid lineage, could 
lead to on-target off-tumour toxicity and serious side effects 
related to therapy.19 Early studies targeting solid tumours 
reported little evidence of clinical effect while there was 
some evidence of on-target, off-tumour toxicity seen using 
CAR targeting carbonic anhydrase-IX16 20 in renal cell 
carcinoma or Her2/neu-specific CAR T cells in colorectal 
cancer (CRC).21 Investigators are therefore still seeking 
for the ideal target antigen that should be highly overex-
pressed on tumour cells compared with normal cells. While 
some recent studies have shown limited clinical effect but 
nowhere near to that seen with CD19 CAR T cell therapy,3 22 
the challenges posed by solid tumours are numerous and 
have been extensively reviewed recently.23–26 In brief, these 
include the on-target off-tumours impact related to expres-
sion of the target on normal tissues, the need for trafficking 
into the tumour microenvironment (TME) and tumour 
stroma, tumour heterogeneity and the requirement to 
overcome the hostile immune suppressive TME, potentially 
leading to CAR T cell exhaustion, clearly requiring the 
further development of the basic CAR approach.27 Several 
options, including third-generation and fourth-generation 
CARs (eg, Armoured CAR, T cells redirected for universal 
cytokine-mediated killing (TRUCKs)), logic gated acti-
vation strategies or the combination of CAR T cells with 
T cell checkpoint inhibitors, are currently under develop-
ment to solve these problems.
nKr-2
NKR-2 are autologous T cells genetically modified to 
express a CAR comprising a fusion of the full-length natural 
killer group 2D (NKG2D) receptor with the CD3ζ signal-
ling domain. NKG2D is a C-type, lectin-like, type II trans-
membrane glycoprotein-activating receptor expressed in 
humans on natural killer (NK), natural killer T, activated 
CD8+ T cells and, under certain conditions, some CD4+ 
and γδ+T cell subsets28 and functioning to target and kill 
cancer or infected cells. In humans, NKG2D is expressed 
as a homodimer that associates with the adaptor molecule 
DNAX-activating protein of 10 kDa (DAP10) to form a 
hexameric structure.29 The interaction with DAP10 is essen-
tial to stabilise the surface expression of NKG2D in T cells 
and to mediate signal transduction and cellular activation 
upon ligand recognition.30 Therefore, while the NKR-2 
CAR format suggests a ‘first-generation’ configuration, 
the NKG2D structural component, via its interaction with 
endogenous DAP10, engages native T cell co-stimulatory 
signalling apparatus to providing a sufficient co-stimulatory 
signal which complements the primary CD3ζ vector-derived 
signal, indicating that the NKR-2 actually works rather like 
a ‘second-generation’ CAR (figure 1). Furthermore, the 
requirement for endogenous DAP10 expression for stable 
expression of NKG2D within cells defines an additional 
embedded safety measure to restrict NKR-2 vector expres-
sion and function specifically to cells expressing native 
DAP10 (eg, T cells).
In humans, eight NKG2D ligands have been identified, 
encoded by different loci on two different arms of the 
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Figure 1 The NKR-2 construct. NKR-2 design contains the full-length human natural killer group 2D (NKG2D) receptor linked 
to the signalling domain of CD3ζ that provides primary signalling (signal 1) to activate T cells upon ligand binding. The naturally 
expressed adaptor molecule DNAX-activating protein of 10 kDa (DAP10) provides secondary signalling (signal 2) which allows 
NKR-2 to work as a second-generation CAR.
chromosome 6 and corresponding to two main fami-
lies: the major histocompatibility complex (MHC) class 
I chain-related proteins (MIC) which include MICA 
and MICB proteins, and the structurally diverse unique 
long 16-binding proteins (UL16-binding proteins or 
ULBP) which include ULBPs 1 to 6.31 The expression 
of these ligands can be induced by stress such as viral 
infection, oxidative or thermal stress, genotoxic drugs, 
DNA-damaging agents, tissue damage, heat shock, 
inflamed tissues (eg, autoimmune diseases) and malig-
nant transformation.32 Importantly, a broad range of 
primary tumours express NKG2D ligands.33 34 While the 
NKG2D ligand expression profile is often heterogeneous, 
the large majority of tumour samples express at least one 
ligand (and often multiple ligands), including haemato-
logical and solid tumour types, implying that the profile 
of ligand expression is suitable to be exploited as a cancer 
therapy.34 Finally, the surface expression of NKG2D 
ligands can be modulated by proteolytic cleavage with 
the release of the soluble ectodomain.35 36 These shed 
NKG2D ligands may downmodulate NKG2D expression 
on NK cells and T cells, contributing to tumour immune 
escape and elevated serum levels were accordingly often 
associated with poor prognosis.35 36
The breadth of ligands targeted by NKG2D provides 
T cells armed with the NKR-2 receptor the potential to 
challenge an extensive range of tumour indications.33 34
Preclinical studies have shown the murine equivalent 
of NKR-2 (chNKG2D T cells) can mediate potent anti-
tumour activity against both haematological and solid 
tumours,37 including highly heterogeneous tumours with 
less than 10% ligand-positive tumour cells (see table 1 for 
a summary of these data).38
Critically, these preclinical data in multiple syngeneic 
tumour models indicate that antitumour efficacy was not 
dependent on lymphodepleting preconditioning, while the 
induction of a tumour-specific adaptive immune response 
by NKR-2 therapy enabled the long-term protective effects 
of the approach.39 Recent data also confirmed that human 
NKR-2 are effective in vivo in a mouse xenograft model of 
human pancreatic cancer.40 Importantly, preclinical data 
suggest four different mechanisms of action of NKR-2, 
including (i) direct cytotoxicity against cancer cells, (ii) anti-
angiogenic activity potentially through targeting of NKG2D 
ligands expressed on tumour neovasculature,41 (iii) modu-
lation of the immune TME through direct targeting of 
immunosuppressive myeloid-derived suppressor cells and 
regulatory T cells (Tregs), and recruitment of myeloid cells 
and activated macrophages,42 43 together resulting in (iv) the 
observed generation of a tumour-specific adaptive immune 
response42–48 (figure 2). Preclinical data also demonstrated 
that NKR-2 rapidly disappeared from tissues by 7 days after 
injection suggesting a short-term persistence of NKR-2 
(without uncontrolled expansion), although being able to 
induce a long-lasting memory host immune response against 
tumour-specific antigens.39 Finally, preclinical data demon-
strated that NKR-2 remained functionally intact in the pres-
ence of soluble MICA at concentrations much higher than 
the physiological concentrations.49
Expressing the NKR-2 CAR into T cells therefore 
allows the NKR-2 cells to present the broad specificity 
characteristic of NK cells while exploiting the migration, 
expansion, long half-life and potential to generate immu-
nological memory characteristic of T cells. In addition to 
direct recognition of tumour cells, targeting of ligands 
expressed on the stroma of the TME can also lead to 
disruption of the essential support mechanisms required 
for tumour cell survival and growth. Moreover, in contrast 
to other single or limited target CAR T cell therapies, the 
fact that NKR-2 targets several ligands from two main 
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Figure 2 NKR-2 different mechanisms of action. Apart from direct cytotoxicity against cancer cells, NKR-2 mode of action 
also involves reduction of blood vessel density indicative of an antiangiogenic activity, modulation of the immunosuppressive 
tumour microenvironment (TME) and induction of a long-term antitumour-specific memory immune response. MDSC, myeloid-
derived suppressor cell.
families putatively decreases the probability of target loss 
and associated relapse after treatment. Further, the lack 
of important in vivo cell expansion and long-term survival 
of NKR-2, and the induction of tumour-specific adaptive 
immunity in the absence of patient preconditioning, also 
bears a safety advantage preventing side effects gener-
ally associated with rapid CAR T cell expansion50 which 
often require development of strategies like embedded 
suicide systems or use of chemotherapy to eradicate the 
CAR T cells.51 52 Collectively, this suggests that exploiting 
the targeting of NKG2D ligands by NKR-2 to fight 
against diverse tumour indications with a single generic 
construct combining two features of innate and adaptive 
immunity provides potentially a new paradigm for CAR 
T cell therapy that the current protocol is designed to 
investigate.
MEthods And AnAlysIs
study objectives
The THerapeutic Immunotherapy with NKR-2 (THINK) 
trial is an open-label phase I study which primarily aims 
to assess the safety and clinical activity of the NKR-2 treat-
ment administered three times every 2 weeks between 
each administration in different tumour types. The study 
is split into two segments each with specific study objec-
tives. The first dose escalation segment focuses on deter-
mining the recommended dose (RecD) of NKR-2 cells for 
second segment of THINK. Segment 2 extends the safety 
study and also investigates initial clinical activity of NKR-2 
across multiple tumour indications. In both segments, 
correlative measures of clinical activity will be examined.
study drug
NKR-2 refers to the viable autologous CD3+ cells 
obtained after transduction of autologous T cells with the 
NKG2D-based CAR, which contains a total viable popu-
lation of at least 80% CD3+ cells, with at least 50% CD3+ 
being transduced. NKR-2 will be supplied cryopreserved 
in bags containing a T cell dose in accordance with the 
dose level which is to be administered.
rationale for the nKr-2 dose and regimen
NKR-2 has been used in the single infusion dose esca-
lation clinical study CM-CS1 (NCT02203825) which 
evaluated the safety and clinical activity of NKR-2 admin-
istration without prior lymphodepleting conditioning in 
patients with two distinct haematological malignancies: 
acute myeloid leukaemia (AML)/higher risk myelodys-
plastic syndrome (MDS) refractory anaemia with excess 
blasts, that are not in remission and for which standard 
therapy options are not available, and relapsed or refrac-
tory progressive multiple myeloma (MM) after several 
lines of standard therapy. The trial has been success-
fully completed with no observed dose-limiting toxicities 
(DLTs) at the highest dose infused (3×107 total cells) and 
initial signs of clinical benefit.53
In preclinical models, the pharmacologically effective 
dose (PED) of the murine NKR-2 ranged from 1×106 cells 
to 7.5×106 cells per dose (intravenous single injection). 
Although a significant antitumour activity was obtained 
with a single injection of murine NKR-2, 100% overall 
survival and complete recovery were obtained following 
repeated three sequential doses of 5×106 cells/mouse 
without any adverse effect.39 42 44 45 Moreover, a treatment 
regimen with 2 weeks’ interval between injections was 
far more successful in terms of activity compared with a 
weekly interval demonstrating that successful treatment 
of established tumours did not require the administration 
of more NKR-2.42 The maximum tolerated dose (MTD) 
after a single intravenous injection was determined to be 
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box Key eligibility criteria
Main inclusion criteria:
 ► Men or women ≥18 years old at the time of signing the informed 
consent form (ICF).
 ► Patient with specific cancer indications (see below).
 ► Disease must be measurable according to the corresponding 
guidelines.
 ► Eastern Cooperative Oncology Group (ECOG) performance status of 
0 or 1 or 2 based on peripheral neuropathy from prior therapies.
 ► Patient with adequate bone marrow reserve, hepatic and renal 
functions.
 ► Left ventricular ejection fraction of >40%.
 ► For patients with solid tumour type, the patient must agree to have 
a tumour biopsy at baseline.
Main exclusion criteria:
 ► Patient with a tumour metastasis in the central nervous system.
 ► Patients who have received another cancer therapy within 2 weeks 
before the planned day for the apheresis.
 ► Patients who receive or are planned to receive any other 
investigational product within the 3 weeks before the planned day 
for the first NKR-2 administration.
 ► Patients who are planned to receive concurrent growth factor, 
systemic steroid or other immunosuppressive therapy or cytotoxic 
agent.
 ► Patients who underwent major surgery within 4 weeks before the 
planned day for the first NKR-2 administration.
 ► Patients who have active infections necessitating the use of 
antibiotics/antivirals treatment.
 ► Patients with history of autoimmune disease.
disease-specific inclusion criteria
Patients must have either:
 ► A documented metastatic or locally advanced colorectal 
adenocarcinoma and having received, being intolerant or having 
refused at least two prior standard cancer therapy regimens as part 
of their primary treatment regimen or part of their treatment for 
management of recurrent/persistent disease.
 ► A documented recurrent epithelial ovarian cancer or fallopian 
tube carcinoma and having received or refused at least two prior 
standard cancer chemotherapy regimens as part of their primary 
treatment regimen or part of their treatment for management of 
recurrent/persistent disease.
 ► An inoperable locally advanced or metastatic urothelial carcinoma 
that has progressed after previous platinum-based chemotherapy.
 ► A metastatic or locally advanced triple-negative breast cancer and 
having received at least one prior cancer therapy regimen as part 
of their treatment for management of recurrent/persistent disease.
 ► A metastatic or locally advanced pancreatic ductal adenocarcinoma 
and having received, being intolerant or having refused at maximum 
two prior lines of standard cancer chemotherapy regimens.
 ► Relapsed or refractory acute myeloid leukaemia (ie, ≥5% blasts 
in bone marrow or in peripheral blood) after one prior therapy or 
patients with myelodysplastic syndrome (ie, ≥5% blasts in bone 
marrow or ≥2% blasts in peripheral blood) or MDS with TP53 
mutation who failed from prior treatments.
 ► Relapsing or refractory/relapsing multiple myeloma with a minimum 
of one prior line of systemic therapy.
1×107 cells, and repeated administration of this dosage to 
healthy and tumour-bearing mice did not produce any 
major toxicities.54
Following these values of PED and MTD, the no-observed 
effect level was defined at 5×106 cells/injection per mouse 
and were identical whatever the tumour-type model (haema-
tological or solid tumour). Using the allometry scaling expo-
nent of 0.75, as defined by Food and Drug Administration 
(FDA) guidelines (USFDA, 2005), human-equivalent PED 
and MTD were therefore estimated at 0.43–3.2×109 and 
4.3×109 cells/injection, respectively. Together these obser-
vations of high tolerability in initial single dose phase I clin-
ical trial coupled with preclinical efficacy experimentation 
strongly support the concept of a dose escalation segment 
of 3×108 –3×109 NKR-2 per infusion given three times each 
separated by a 14-day interval.
Patient population
Refractory or relapsing patients with metastatic or locally 
advanced CRC, urothelial carcinoma, triple-negative 
breast cancer (TNBC), pancreatic cancer, recurrent 
epithelial ovarian and fallopian tube carcinoma, AML/
MDS and MM, which failed from standard treatments, 
will be recruited into this protocol (the key inclusion and 
exclusion criteria are presented in box).
The study will enrol patients in different countries in 
Europe and in USA with a dose escalation segment open 
to a restricted academic network in Belgium and USA. 
List of study sites can be obtained on  clinicaltrials. gov 
(NCT03018405).
The tumour types targeted in this protocol were selected 
primarily based on their high expression of the NKG2D 
ligands (with a prevalence of 78–100% tumour samples 
expressing at least one ligand).33 34 Furthermore, NKG2D 
ligand expression is a dynamic and context-dependent 
process, quickly varying over time in response to cytokines 
in the TME and evolving along with tumour progression, 
local inflammatory responses and treatments,33 34 hence 
difficult to assess. Finally, even if NKG2D ligand expression 
is heterogeneous with respect to the exact ligands found, 
based on preclinical data, potential therapeutic benefit 
might be achieved in patients with highly heterogeneous 
tumours38 or even tumours considered as ‘negative’ for 
NKG2D ligands because of a NKG2D ligand-positive TME 
and/or neovasculature and/or activation of host immune 
system.42–48 Thus, no eligibility criteria were based on the 
individual expression profile of NKG2D ligands and no 
diagnostic test for ligand expression was used for recruit-
ment into this study. Correlative studies, however, will be 
carried out during the trial and will attempt to investigate 
the expression profile of patient tumours with clinical 
response.
thInK study design
THINK phase I study will contain two consecutive 
segments: a dose escalation and an expansion segment 
(figure 3).
The dose escalation design will include three dose levels 
of NKR-2. The assumption is made that the safety profile 
of the treatment could be different in haematological 
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Figure 3 Overview of the study design. AML, acute myeloid leukaemia; CRC, colorectal cancer; MDS, higher risk 
myelodysplastic syndrome; MM, multiple myeloma; ORR, objective response rate; RecD, recommended dose; TNBC, triple-
negative breast cancer.
versus solid tumour types. Therefore, it will be assessed 
separately in two different arms, one in solid tumours 
(CRC, urothelial carcinoma, TNBC, pancreatic cancer 
or epithelial ovarian and fallopian tube carcinoma) and 
one in haematological tumours (AML/MDS or MM). 
Each arm will use a 3+3 design to determine the RecD of 
the NKR-2 treatment for the corresponding cohorts in 
the expansion segment, as based on the occurrence of 
DLTs (ie, three patients will be evaluated per dose level 
for each arm of the segment and three additional patients 
will be added if one out of three patients in this cohort 
experiences a DLT to further assess the safety of the treat-
ment). The sample size of the dose escalation part will be 
between 2 and 18 patients per arm. Six patients will be 
treated at the MTD (or highest dose level if no DLT was 
observed).
The RecD will be the MTD unless in case no MTD is 
determined in the dose escalation segment of the study. 
In the latter, the RecD will be highest dose evaluated in 
the dose escalation segment.
The RecD will be further evaluated in the expansion 
segment of the study to assess separately the safety profile 
and initial clinical activity of the NKR-2 treatment in 
seven cohorts of patients with the distinct tumour types 
(up to 14 patients per tumour type). The expansion 
segment in haematological and solid tumours will be 
initiated as soon as their respective dose escalation arm 
defines the RecD. During this segment, the RecD can still 
be adapted according to predefined safety rules in any 
specific tumour type. The statistical analysis is planned 
in three steps. A futility analysis will be conducted sepa-
rately in the first 14 patients with a solid tumour and the 
first 6 patients with a haematological tumour type. These 
number of patients have been defined to have a 0.05 
probability of finding 0 objective response at this step if 
the true probability of response were 0.2 (solid) or 0.4 
(haematological). Subsequently, futility (no response 
in the first seven patients) and efficacy (three or more 
responses in 14 patients) will be tested by cohort, based 
on the Simon’s two-stage optimal design. The assump-
tions are: type I error rate=0.15, power=0.80 and response 
probability of poor drug=0.10/beneficial drug=0.30. 
In total, up to 86 patients are expected to be enrolled 
in the expansion segment (in addition, the six patients 
from each arm of the dose escalation segment who were 
treated at the RecD will be included in these expansion 
analyses).
treatment regimen
Three NKR-2 dose levels will be evaluated during this 
study, that is, 3×108, 1×109 and 3×109 NKR-2 for each injec-
tion (adjusted to 4.6×106, 1.5×107 and 4.6×107 NKR-2/
kg, respectively, for patients with body weight below or 
equal to 65 kg) with a schedule of administration of three 
NKR-2 doses administered with a 2-week interval per 
patient. No systemic lymphodepleting preconditioning 
will be performed prior to NKR-2 injections.
trial endpoints
The primary endpoint of the dose escalation segment will 
be the occurrence of DLTs in all patients during the 
study treatment until 14 days after the last study treat-
ment administration. Secondary endpoints will include the 
(i) occurrence of adverse events (AEs) and serious adverse 
events (SAEs) during the study treatment, (ii) occurrence 
of objective clinical response at D57, M3, M6, M9, M18 
and M24 after first NKR-2 administration and according 
to international guidelines and (iii) progression-free 
survival (PFS) and overall survival (OS), and duration of 
response for patients with objective response up to 2 years 
after first NKR-2 administration.
The primary endpoint of the expansion segment will be 
the objective response rate (ORR) at D57, M3, M6, M9, 
M18 and M24 after first NKR-2 administration. Secondary 
endpoints will include the (i) PFS and OS, (ii) duration of 
response for patients with objective response up to 2 years 
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Figure 4 Overview of study phases. NKR-2 will be infused on days 1, 15 and 29. Tumour assessment will be done by tumour 
imaging and blood sampling for solid tumours and tumour imaging, blood, urine and bone marrow sampling for haematological 
tumours. BM, bone marrow; D, day; ICF, Informed Consent Form; M, month.
after first NKR-2 administration and (iii) occurrence of AEs 
and SAEs and DLTs during the study treatment.
The overall aim of this segment is to understand the 
safety profile and develop initial observations of clinical 
activity in a cohort of up to 14 patients that support a 
deeper assessment of clinical efficacy of NKR2 in larger 
patient cohorts within a phase II clinical study.
Response to treatment will be assessed according to 
standard Response Evaluation Criteria In Solid Tumors 
(RECIST) criteria (version 1.1) for solid tumours or 
international recommendations for response criteria in 
haematological tumours. Apart from the visits scheduled 
per protocol, tumour assessment might also be performed 
at any time if considered as needed per investigator’s 
decision (eg, progression suspicion) and with regard to 
the RECIST 1.1. response confirmation.
study duration
For each patient, the overall study duration will be 
15 years. The study consists of a screening phase, a 
treatment administration phase, a treatment follow-up 
phase and a long-term safety follow-up (figure 4). The 
duration of the administration phase will be 8 weeks, 
from Visit D1 to Visit D57. The duration of the treat-
ment follow-up phase will be 22 months, from the 
end of the administration phase on D57 (Week 8) to 
Visit M24.
As per regulatory requirements, patients who received 
at least one NKR-2 treatment will need to be followed 
annually for a period of 15 years. Therefore, patients 
will also follow a long-term safety follow-up that will last for 
up to 15 years after the day of the first NKR-2 adminis-
tration to collect safety data for 13 additional years. The 
surveillance will mimic as much as possible the standard 
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follow-up of the respective tumour type, including moni-
toring of important safety parameters.
Patients may be withdrawn from the study treatment 
or from the study at any time at the patients’ discretion 
or at their investigator’s discretion. The investigator will 
document on the patient’s record whether the decision 
to discontinue treatment and/or study participation was 
made by the patient or the investigator and which reason 
applies.
In case of absence of disease progression at M24, PFS 
and OS as clinical endpoints will be followed up on a 
yearly basis or at ad hoc basis, that is, in case of progres-
sion/relapse suspicion. In case of disease progression at 
M24 or at any time before, the patient will be still asked 
to attend simplified follow-up procedures, which will 
include (i) record of survival status, (ii) medication status 
and (iii) blood sampling for viral copy number (VCN) 
and replication competent retrovirus (RCR) assessment. 
Clinical progression at the end of the treatment phase 
(D57) will not to be considered as a criterion for with-
drawal from the study and will allow the continuation 
of the active follow-up of the patient with or without the 
initiation of a new anticancer therapy.
Enrolment rules
There is no requirement for specific recruitment of each 
individual tumour indication to corresponding arm 
within the dose escalation phase, but each dose level should 
enrol at least two different types of cancer. In each arm, 
patients will be enrolled at the next dose level when all 
evaluable patients at the same dose level have completed 
the safety period of 14 days after last NKR-2 injection. 
Within each dose level, patients will be enrolled as soon 
as the previous patient has received at least one NKR-2 
administration and has completed the 14-day safety 
period after the first injection.
Enrolment in the expansion segment of the study will 
be performed in three steps, with a statistical analysis at 
the end of each step (see Adverse events, serious adverse 
events and dose-limiting toxicities section). Within each 
step, all patients can theoretically be enrolled at the same 
time.
Approximately 15 centres are expected to be initiated 
for patient enrolment in the expansion segment. Recruit-
ment is anticipated to be completed within approximately 
24 months. If this target is not met, then the recruitment 
period may be extended accordingly.
Adverse events, serious adverse events and dose-limiting 
toxicities
All AEs starting from registration to 28 days after the last 
study treatment (Visit D57) must be recorded into the 
Adverse Event form in the patient’s electronic case report 
form (eCRF), irrespective of intensity or causality with 
study treatment.
To ensure patient safety, every SAE, regardless of 
suspected causality, occurring after the patient enrolment 
and until the administration phase concluding visit (at 
D57) must be reported to the sponsor within 24 hours of 
learning of its occurrence. Any SAEs experienced outside 
this period will only be reported to the sponsor if the 
investigator suspects a causal relationship to the study 
participation or if fatal SAEs occur after signature of the 
Informed Consent Form (ICF).
DLT refers to a toxicity that is experienced during 
treatment and within 14 days following any NKR-2 dose, 
is new and at least possibly related to study treatment. 
This includes any Grade 3 or higher toxicity or Grade 2 
or higher autoimmune toxicity that cannot be controlled 
to Grade 1 or less within 72 hours with appropriate treat-
ment, with the exception of Fever Grade 3 and immediate 
hypersensitivity reactions occurring within 2 hours of cell 
infusion that are reversible to a Grade 2 or less within 
24 hours of cell administration with standard therapy.
Whenever a patient experiences toxicity that fulfils the 
criteria for a DLT, the study treatment will be interrupted. 
The standard time period for collecting and recording 
DLTs will be 14 days after each study treatment admin-
istration. AEs/SAEs that meet the definition of DLTs 
but that are reported outside of this time window will be 
reported as AEs/SAEs but not as DLTs.
The standard time period for collecting and recording 
pregnancy will begin at the first receipt of the product 
and last until the end of the study.
In addition to the above-mentioned reporting require-
ments and in order to fulfil international reporting 
obligations, SAEs that are related to study participation 
(eg, protocol-mandated procedures, invasive tests, a 
change from existing therapy) will be collected and 
recorded from the time the patient consents to partici-
pate in the study until she/he is discharged.
conduct of analysis and statistical considerations
All statistical analyses will be performed using SAS (SAS 
Institute) and/or StatXact (Cytel Software Corp) soft-
wares. The results will be reported per dose level/tumour-
type cohort and overall.
demographic characteristics
Physical examination (age, gender and race), medical 
history and baseline tumour characteristics will be tabu-
lated and analysed with appropriate descriptive statistics 
on the total treated population.
The analysis of safety will be performed on the total 
treated population. All the AEs will be graded according 
to the National Cancer Institute Common Terminology 
Criteria for Adverse Events (NCI-CTCAE), Version 4.03 
and will be coded to the preferred term level using the 
Medical Dictionary for Regulatory Activities (MedDRA). 
A summary of AEs by maximum grade and cohort will be 
generated. The same analysis will be presented for SAEs 
and events with a suspected relationship to the study 
treatment. A summary of AEs by maximum grade and 
cohort per treatment dose will also be performed. SAEs, 
DLTs and discontinuation due to AEss will be described in 
detail by patient narratives.
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A summary of the concomitant medications, classified 
by Anatomical Therapeutic Chemical (ATC) term, will 
be displayed by cohort. Individual listing of concomitant 
medications per patient and per time point will also be 
provided. Finally, the total number of study treatments 
administered to each patient and the length of active 
follow-up will be summarised.
The analysis of clinical activity will be performed on the 
total treated population, that is, all patients who received at 
least one NKR-2 treatment (in case of patient’s withdrawal 
prior the end of the administration phase). Sensitivity 
analyses related to the clinical activity endpoints will be 
performed on the according to protocol population which 
includes all evaluable patients who have complied with all 
the procedures defined in the protocol up to concluding 
visit.
The first ORR will be assessed at Visit D57. The 
occurrence and duration of objective clinical response 
Complete response (CR), partial response (PR) and 
stable disease (SD) will be reported. Disease progres-
sion, including death, during the study will be described. 
Estimates of the rates of best clinical response and their 
95% CIs will be reported. Kaplan-Meier curves will be esti-
mated for PFS and OS.
In addition, other exploratory analyses may be 
performed, that is, the clinical activity may be assessed 
in subpopulations based on the NKG2D ligands tumour 
expression, types of ligands expressed in tumour, serum 
levels of soluble NKG2D ligands and so on.
In the dose escalation segment, safety data will be 
monitored closely on an ongoing basis. The main analysis 
(leading to the selection of the RecD) will be conducted 
separately in each arm once all patients in the last dose 
level have received the three NKR-2 administrations and 
have completed the safety period (D43). All data related 
to the primary endpoints of the study will be analysed. 
The final analysis will be performed once all patients 
have attended the concluding visit of the follow-up phase 
(M24) or have been withdrawn from the study.
The expansion segment of the study will proceed in 
three steps, with a statistical analysis at the end of each 
step (figure 3). These steps aim to stop the study for 
futility in specific cohorts or specific tumour types in 
case of no (sufficient) responders in the corresponding 
cohorts at the time of analysis.
An interim analysis for futility will be performed on the 
first 14 patients over all 5 cohorts of patients with solid 
tumour types and on the first 6 patients over the 2 cohorts 
of patients with haematological tumour types who have 
either completed the administration phase (D57) or have 
withdrawn from the study.
The second step consists in cohort futility analyses after 
the first seven cancer patients in each tumour type have 
either completed the administration phase (D57) or have 
withdrawn from the study. At this step, an evaluation of 
the safety of the NKR-2 treatment in each cohort will also 
be performed on the first six patients who completed the 
6-week treatment period (D43) or had a DLT. This will 
allow to adapt the RecD in any specific cohort (tumour 
type) according to both safety rules and futility analysis. 
Indeed, if, and as soon as, two or more DLTs have been 
reported within a specific cohort, and the criterion for 
futility was not reached, the next patients enrolled in 
this cohort will be treated at the next lower dose level. In 
contrast, if no DLT has been reported within a specific 
cohort, and the criterion for futility was not reached at 
Step 2, the next patients enrolled will be treated with the 
next higher dose level.
Finally, the final evaluation of the objective clinical 
response rate will be evaluated once all the first 14 cancer 
patients in each cohort have either completed their 
administration period (D57) or have withdrawn from 
study due to disease progression or DLT. If, in any cohort, 
there are >2 out of 14 patients presenting an ORR, the 
study will be considered as successful in this tumour type.
correlative studies
Peripheral blood samples, bone marrow aspirates from 
patients with haematological malignancies, as well as 
tumour biopsies from patients with solid malignancies, 
will be collected at regular time points during the study 
(see figure 4) and used to determine NKR-2 persistence 
post-infusion (using a VCN test) and assess the presence 
of RCR. Systemic cytokine levels in peripheral blood and 
levels of tumour-related biomarkers (in the serum, bone 
marrow or urine samples) will also be assessed to deter-
mine whether correlates of NKR-2 activity can be identi-
fied. Evaluation and characterisation of the NKR-2 mode 
of action involving the characterisation of the pre-existing 
and post/during therapy humoural and cellular immune 
responses will be done on blood samples collected at 
baseline and post-NKR-2 infusion. Finally, the correlation 
with the tumour expression of NKG2D ligand in tumour 
tissues or cells (type and level) and NKR-2 activity, the 
characterisation of the TME, the NKR-2 infiltration and 
the modulation of the local tumour environment of this 
new type of T cell therapy will be evaluated.
toxicity management
As previously mentioned, the use of CAR T cells is limited 
by potentially severe toxicities, including CRS, neurotox-
icity and tumour lysis syndrome (TLS), on-target off-tu-
mour toxicity (related to recognition of the target antigen 
on normal tissues), clonality and insertional oncogenesis, 
vector persistence and immunogenicity. While these 
events may have been seen in relation with other CAR 
T cell therapies, and are provided for information, there 
are currently no events considered as expected for NKR-2 
therapy (which can be different from other CAR T cell 
studies based on the unique mode of action) and all 
serious adverse reactions (SARs) will be considered as 
suspected unexpected SARs (SUSARs).
The management of toxicities related to CAR T cell 
therapies was described elsewhere11 12 55 but is evolving 
with everyday new information available from ongoing 
studies. Sites will be kept informed all along the study for 
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any new therapeutic options modifications or standardi-
sation between the different sites.
Briefly, CRS toxicity is currently of highest concern in the 
field. It is caused by a release of inflammatory cytokines such 
as interleukin (IL)-6, IL-2, Interferon (IFN)-γ and Tumour 
Necrosis Factor (TNF)-α, following the recognition of the 
target antigen, resulting in a systemic inflammatory response 
similar to sepsis. Therefore, CRS will correlate with both effi-
cacy and toxicity in patients receiving T cell-engaging ther-
apies. Tocilizumab (anti-IL-6) will be used as the first-line 
agent in the treatment of CRS. If the patient’s condition does 
not improve or stabilise within 24 hours of the tocilizumab 
dose, administration of a second dose of tocilizumab and/or 
a second immunosuppressive agent (such as corticosteroids) 
will be considered, based on the CRS revised grading system 
created by Lee et al56 to identifying severity and implementa-
tion of optimal care strategies for CRS.
TLS resulting in renal insufficiency, rapidly rising 
uric acid level or evidence of organ dysfunction will be 
managed with fluids and rasburicase as needed and as 
determined by the treating physicians.
Further, as NKG2D ligands may be upregulated on 
stress signals, expression of ligands on non-cancer cells 
can be expected in tissues that are actively infected or 
inflamed or experienced cell stress of other aetiology. 
Infections could therefore invoke a significant inflamma-
tory response by NKR-2 by potentially inducing a CRS due 
to the increased recognition of ligands by NKR-2 cells. 
Therefore, any inflammation, infection, concurrent or 
previous treatment with anticancer therapies will be care-
fully registered and any Grade 2 or higher autoimmune 
toxicity will be closely followed to detect any evidence of 
on-target off-tumour toxicity. Evidence of acute infection, 
as well as fever of 38°C/100 °F or above, will be therefore 
considered as an exclusion criterion at screening (see 
box) or postponement criterion when observed during 
the treatment phase. In the latter, all study procedures 
and treatment administration will be resumed where it 
was left as soon as the patient’s condition allows (within 
4 weeks after the scheduled treatment date) or at the 
investigator’s discretion after steering committee and 
sponsor approvals.
Since NKR-2 construct consists entirely of human 
sequences, it is not expected to result in immunogenicity 
sometimes observed with other CARs using scFv from 
murine origin (see section Introduction), and therefore 
multiple NKR-2 injections are allowed without the antici-
pated risk of humoural immune responses.
Uncontrolled expansion and proliferation of the trans-
formed cells increase the risks for onset of CRS and other 
CAR-associated toxicities. However, in contrast to more 
classical CAR T cell therapies, NKR-2 demonstrated 
neither significant in vivo expansion nor long-term 
persistence until now,39 but since this is the first trial with 
NKR-2 administrated as multiple doses, the persistence of 
NKR-2 will be nevertheless carefully monitored post-infu-
sion as mandatory exploratory research. If uncontrolled 
T cell proliferation occurs (Grade 3 or 4 toxicity related 
to NRK-2), and as it was reported that CAR-associated 
toxicity responds to systemic corticosteroids, patients may 
be treated with corticosteroids and/or chemotherapy to 
eradicate the CAR T cells.57 Patients will be treated with 
pulse, followed by a rapid taper.
Finally, following FDA recommendation for retroviral 
and lentiviral vector based gene therapy products, the 
patient monitoring schedule will also include analysis of 
the RCR of patient samples up to 15 years after CAR T 
cell injections.
dIscussIon
The THINK trial aims primarily to determine the safety 
and clinical activity of NKR-2 cell therapy, without precon-
ditioning chemotherapy, in patients with advanced 
cancer. The dose escalation phase of the trial is designed 
to determine the RecD in haematological and solid 
tumours, which then is used in the expansion phase to 
assess clinical responses separately in seven different indi-
cations. Due to the multitargeting specificity of NKR-2, 
the dose escalation and subsequent expansion segments 
are designed to facilitate a rapid assessment of NKR-2 
activity across a range of tumours. This is advantageous 
since the assessment of safety and any evidence of clinical 
activity will be suitably evaluated across cancer types using 
a consistently produced cell product, thereby avoiding 
issues that arise in multiple single tumour indication 
trials testing a single T cell product. Interestingly, the 
number of ligands targeted by NKR-2 (eight ligands from 
two main families), combined with their stress-induced 
tissue expression, also limits the potential risk of clonal 
selection or antigen loss after injection, which has been 
observed for classical CAR constructs targeting a single 
antigen. This is expected to translate into limiting the risk 
for potential relapse.
For patients, the lack of preconditioning chemotherapy 
removes the need for an inpatient stay during the tran-
sient period of lymphodepletion translating to a likely 
improved patient experience of the trial. Additionally, the 
absence of preconditioning will also reduce the potential 
toxicity of this treatment and facilitate providing a thera-
peutic solution to a larger patient population, including, 
notably, the elderly population.
The challenge facing classical CAR T cell therapies in 
the human patient with advanced cancer (beyond B cell 
malignancies) is major and, in the solid tumour situation, 
requires the cells to traffic to sites of tumour, overcome 
the highly suppressive TME and initiate direct tumour 
cell killing to drive a sustained antitumour response.23–25 
Based on the different intrinsic mechanisms of action of 
NKR-2 observed in preclinical experiments on various 
tumour models, NKR-2 should overcome, at least 
partially, the local immunosuppression and target expres-
sion heterogenicity in tumour tissues, while, because of 
its effect on tumour vasculature, trafficking into tumours 
might also be enhanced. Furthermore, the multiple 
infusion strategy was also found to increase activity and 
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infiltration into tumours of other short-term persistent 
CAR T cells (mesothelin-specific RNA CAR T cells),58 over-
come the potential tumour-induced T cell dysfunction on 
interaction of CAR T cells with the immunosuppressive 
tumour microenvironment23 while being well tolerated in 
humans.59 Consequently, compared with classical CARs, 
clinical activity in solid tumours might be observed after 
treatment with NKR-2, without any construct modifica-
tion nor combination with other immunotherapies. Since 
THINK is the first trial to evaluate the potential clinical 
activity of a multiple NKR-2 administration schedule in 
solid tumours, it offers a real opportunity compared with 
classical CAR T cells within the solid tumour-type field, 
where therapeutic options are limited. Further impacting 
the tumour environment through combinations of 
chemotherapy or immune modulation will constitute 
subsequent steps to consider once we have progressed 
sufficiently in the THINK trial and demonstrated safety 
of NKR-2 administrations.
The multiple infusion strategy, absence of precondi-
tioning chemotherapy, diversity of putative mechanisms 
of action, as well as the diversity of tumour types that can 
potentially be targeted, therefore stand the NKR-2 CAR 
T cell approach described in this protocol apart from the 
current ‘gold standard’ CAR T cell therapy paradigm. In 
this context, the THINK trial provides a first approach 
of a global comprehensive clinical programme embed-
ding other phase I clinical protocols that will evaluate 
the combination of the NKR-2 with specific anticancer 
treatments and the locoregional administration, among 
others.
Ethics and dissemination
The investigator is responsible for ensuring the study is 
conducted in accordance with procedures and evalua-
tions described in the clinical protocol. Deviations from 
the protocol shall not be made without prior approval 
by the sponsor, except to treat a medical emergency and 
reduce immediate risk to the patient. In such a case, the 
investigator shall immediately notify the independent 
ethics committee (IEC) or institutional review board and 
the sponsor, according to local requirements.
If changes to the protocol are deemed necessary, a 
written amendment should be prepared and signed by 
the investigator and the sponsor and approved by the 
IEC and applicable competent authorities prior to being 
implemented.
The steering committee will be composed of three 
members independent of investigators and the sponsor. 
The role of the steering committee will be to advise on 
events which may impact the general process of the clin-
ical study. All safety data will be made available to the 
steering committee in a way that the steering committee 
can timely advise.
Celyad or designee will host specific safety data review meet-
ings (or teleconferences) on a regular basis during the study 
to discuss and evaluate all of the gathered safety data. This 
safety follow-up will include teleconference at the end of 
each dose level of the phase I dose escalation arms and at 
any new relevant safety event onset (ie, DLT, treatment-re-
lated SAE, SUSAR). In addition, members of the steering 
committee will be requested to review the clinical study 
report(s) generated from data collected in this study.
Clinical data review meetings will be performed at the 
different study interim analyses for futility by the Celyad clin-
ical trial team and the steering committee in specific. At the 
time of the interim analyses, the best overall response for 
each patient will be derived from the overall lesion response 
assessments recorded in the eCRF. This will be used to calcu-
late the ORR in the respective group(s).
For the purpose of compliance with Good Clinical 
Practises (GCP) and competent authorities guide-
lines, it may be necessary for the sponsor or a compe-
tent authority to conduct a site audit. This may occur 
at any time from start to after conclusion of the study. 
Therefore, when an investigator signs the protocol, he 
agrees to permit drug competent authorities and the 
sponsor audits, providing direct access to source data/
documents.
Written informed consent will be taken from all partici-
pants. The patient will be asked to read and review the 
document. On reviewing the document, the investi-
gator (or delegate) will explain the research study to the 
patient and answer any questions that may arise. The 
patients consent should be appropriately recorded by 
means of the patients personally dated signature prior to 
any procedures being done specifically for the study. The 
patients should have the opportunity to discuss the study 
with their surrogates or think about it prior to agreeing 
to participate. The patient’s participation is voluntary and 
the patient may withdraw consent at any time throughout 
the course of the study.
Patient confidentiality
Patient confidentiality is strictly held in trust by the partic-
ipating investigators, their staff, and the sponsor(s) and 
their agents. This confidentiality is extended to cover 
testing of biological samples and genetic tests in addi-
tion to the clinical information relating to participating 
patients.
The study protocol, documentation, data and all other 
information generated will be held in strict confidence. 
No information concerning the study or the data will be 
released to any unauthorised third party, without prior 
written approval of the sponsor.
The investigator remains accountable for the study data. 
Final data set will be stored in a central database main-
tained by the sponsor. At the conclusion of the study, the 
sponsor will archive the study data in accordance with 
internal procedures. All information provided by the 
sponsor and all data and information generated by the 
site as part of the study (other than a patient’s medical 
records) remain the sole property of the sponsor.
The results of this study will be disseminated through 
presentation at international scientific conferences and 
reported in peer-reviewed scientific journals.
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The sponsor holds and will maintain an adequate 
insurance policy covering damages arising out of Celyad’s 
sponsored clinical studies. Financial compensation to 
investigators and/or institutions will be in accordance 
with the agreement established between the investigator 
and/or institutions and the sponsor.
The THINK trial (A Dose Escalation Phase I Study to 
Assess the Safety and Clinical Activity of Multiple Cancer 
Indications) is currently recruiting participants in Europe 
and USA.
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